Income Statement (Annual)

ORGS / Orgenesis, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000 except per share units.

2010 2011 2012 2013 2014 2015 2016 2017
Revenues 0 0 - - 0 2,974 6,397 10,089
Cost Of Revenue - - - - 0 3,880 7,657 6,807
Gross Profit - - - - 0 -906 -1,260 3,282
Research And Development Expense - 0 2,309 1,452 1,549 1,067 2,157 2,478
Amortization Of Intangible Assets - - - - 0 1,203 1,620 1,631
General And Administrative Expense 3 1 2,680 4,008 3,027 4,035 6,240 9,189
Other Operating Income - - - - - - - -
Operating Income Loss - - - - -4,577 -7,211 -11,400 -11,230
Other Nonoperating Income Expense - 0 -10 -79 -927 1,850 -1,260 -2,447
Income Loss From Equity Method Investments - - - - - - - -
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments -36 -72 -4,989 -5,461 -4,577 -5,361 -12,660 -13,677
Income Tax Expense Benefit 0 0 - - 0 -900 -1,547 -1,310
Profit Loss -36 -72 - - - - - -
Net Income Loss Attributable To Redeemable Noncontrolling Interest - - - - - - - -
Earnings Per Share
  Earnings Per Share Basic - - - 0 0 0 0 0
  Earnings Per Share Diluted - - - 0 0 0 0 0
Weighted Average Number Of Shares Outstanding Basic
  Weighted Average Number Of Shares Outstanding Basic - - - 50,484 54,163 55,798 8,522 9,680
  Weighted Average Number Of Diluted Shares Outstanding - 80,500 54,265 50,484 54,722 56,921 8,522 9,714
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
  Net Income Loss -36 -72 -4,998 -5,539 -5,504 -4,461 -11,113 -12,367
  Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent - - - 0 -18 -1,268 81 2,630
Comprehensive Income Net Of Tax - -72 -4,998 -5,539 -5,522 -5,729 -11,032 -9,737

Peers - Pharmaceutical Preparations (2834)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 68619K105